IVITX
Price
$23.05
Change
-$0.41 (-1.75%)
Updated
Feb 21 closing price
Net Assets
157.69M
VVIAX
Price
$68.79
Change
-$0.81 (-1.16%)
Updated
Feb 21 closing price
Net Assets
192.55B
Ad is loading...

IVITX vs VVIAX

Header iconIVITX vs VVIAX Comparison
Open Charts IVITX vs VVIAXBanner chart's image
VY® Invesco Growth and Income S2
Price$23.05
Change-$0.41 (-1.75%)
VolumeN/A
Net Assets157.69M
Vanguard Value Index Adm
Price$68.79
Change-$0.81 (-1.16%)
VolumeN/A
Net Assets192.55B
IVITX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
IVITX vs. VVIAX commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IVITX is a Hold and VVIAX is a StrongBuy.

Ad is loading...
FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 193B vs. IVITX (158M). VVIAX pays higher dividends than IVITX: VVIAX (2.36) vs IVITX (1.43). IVITX was incepted earlier than VVIAX: IVITX (22 years) vs VVIAX (24 years). IVITX has a lower initial minimum investment than VVIAX: IVITX (0) vs VVIAX (3000). VVIAX annual gain was more profitable for investors over the last year : 13.46 vs. IVITX (3.21). VVIAX return over 5 years is better than : 47.22 vs. IVITX (9.27).
IVITXVVIAXIVITX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence22 years24 years-
Gain YTD3.8294.16492%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets158M193B0%
Annual Yield % from dividends1.432.3661%
Returns for 1 year3.2113.4624%
Returns for 3 years-9.1423.94-38%
Returns for 5 years9.2747.2220%
Returns for 10 years-13.96105.55-13%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GTBP2.150.02
+0.94%
GT Biopharma
OSBC18.33-0.42
-2.24%
Old Second Bancorp
CNM50.97-1.45
-2.77%
Core & Main
IBRX3.42-0.22
-6.04%
ImmunityBio
CRDL1.20-0.10
-7.69%
Cardiol Therapeutics